About
SphereBio redefines the next generation of oncology immunotherapies through a programmable intracellular delivery platform that overcomes the industry's main biological hurdle: endosomal escape. Our proprietary technology combines artificial intelligence and biological nanovesicles, called XSpheres™, to deliver the complete repertoire of tumor antigens directly into the cellular cytosol, achieving immune coverage sixty-five times superior to traditional mRNA vaccines.
What is your business/industry sector?
Biotech, Pharma and Cosmetics